Moderate to Vigorous Exercise Linked to Reduced Fat in Postmenopausal Women
the Cancer Therapy Advisor take:
Reductions in total body fat and other adiposity outcomes in postmenopausal women were observed to be greater in those who exercised moderately to vigorously 300 minutes per week compared to 150 minutes per week, according to an article published online in the journal JAMA Oncology.
Participants in the study included 400 previously inactive, postmenopausal women who were disease-free, nonsmokers, and nonusers of exogenous hormones with a body mass index 22 to 40.
Two cohorts of participants were established: group one completed 30 minutes of moderate-volume activity per session and group two completed 60 minutes of high volume activity per session. Both groups participated in 5 days of aerobic exercise per week with 3 days supervised and 2 days unsupervised, and were asked to not change their usual diet.
Results showed 384 out of the 400 women provided adiposity measurements at baseline and follow-up. The high-volume group had a median adherence at full prescription of 254 women (166-290) compared to the moderate-volume group with a median adherence of 137 (11-150).
The high-volume group’s mean reduction in total body fat was significantly greater than the moderate-volume cohort (least-squares mean difference, −1.0%; 95% CI: −1.6%, −0.4%; P=0.002). Similarly, the subcutaneous abdominal fat and waist to hip ratio decreased significantly more in the high-volume group (least-squares mean difference, −10.8; 95% CI: −19.5, −2.2 cm2; P=0.01) compared to the moderate-volume group (−0.01; 95% CI: −0.02, 0.00: P=0.04).
The two groups did not have a reported difference between changes in weight and intra-abdominal fat (least-squares mean difference, −0.7, 95% CI: −1.6, 0.2 kg; P=0.11, and −1.5; 95% CI: −5.9, 2.9 cm2; P=0.50, respectively).
Reductions in body fat and other adiposity outcomes in postmenopausal women were greater in those who exercised moderately to vigorously.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Metastatic Prostate Cancer Responds to Novel Radiation Therapy
- Clinical Applications of Liquid Biopsies in Cancer
- Two-Drug Combination Superior to Sunitinib in Patients With Untreated Advanced Renal Cell Carcinoma
- Radical Prostatectomy Compared With Watchful Waiting in Localized Prostate Cancer
- Immunotherapy in Glioblastoma: Peaks and Pits
- OS and PFS End Points Not Met in Phase 3 Trial of Pembrolizumab in Advanced HCC
- No Benefit Observed With Osimertinib Plus Durvalumab in EGFR-Mutated NSCLC
- Evidence of the Role of Circulating Insulin in Renal Cell Carcinoma Risk
- Treatment Guidelines in Cancer: Assessing Industry Influence on Recommendations
- American Society of Breast Surgeons Recommends Genetic Testing for All Patients With Breast Cancer